Citi analysts have recommended that investors sell their Moderna shares, citing that the company's revenue and profit forecasts do not support the current high valuation of its stock. This comes after Moderna's stock has seen an increase of over 600%. Analysts believe that the market's expectations may be overly optimistic given the company's financial outlook.
Investors should monitor Moderna's upcoming quarterly earnings report closely, as it will provide insight into whether the company's financial performance aligns with current stock valuations. A significant deviation could lead to increased volatility in the stock price.